Jump to: navigation, search
Tiratricol 3D ball.png
Systematic (IUPAC) name
[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
CAS number 51-24-1
ATC code H03AA04 D11AX08
PubChem 5803
DrugBank DB03604
Chemical data
Formula C14H9I3O4 
Mol. mass 621.932 g/mol
SMILES eMolecules & PubChem
Synonyms 3,3',5-triiodothyroacetic acid
Pharmacokinetic data
Bioavailability  ?
Protein binding Presumed high
Metabolism Hepatic glucuronidation
Half life  ?
Excretion Biliary
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

WikiDoc Resources for Tiratricol


Most recent articles on Tiratricol

Most cited articles on Tiratricol

Review articles on Tiratricol

Articles on Tiratricol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tiratricol

Images of Tiratricol

Photos of Tiratricol

Podcasts & MP3s on Tiratricol

Videos on Tiratricol

Evidence Based Medicine

Cochrane Collaboration on Tiratricol

Bandolier on Tiratricol

TRIP on Tiratricol

Clinical Trials

Ongoing Trials on Tiratricol at Clinical Trials.gov

Trial results on Tiratricol

Clinical Trials on Tiratricol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tiratricol

NICE Guidance on Tiratricol


FDA on Tiratricol

CDC on Tiratricol


Books on Tiratricol


Tiratricol in the news

Be alerted to news on Tiratricol

News trends on Tiratricol


Blogs on Tiratricol


Definitions of Tiratricol

Patient Resources / Community

Patient resources on Tiratricol

Discussion groups on Tiratricol

Patient Handouts on Tiratricol

Directions to Hospitals Treating Tiratricol

Risk calculators and risk factors for Tiratricol

Healthcare Provider Resources

Symptoms of Tiratricol

Causes & Risk Factors for Tiratricol

Diagnostic studies for Tiratricol

Treatment of Tiratricol

Continuing Medical Education (CME)

CME Programs on Tiratricol


Tiratricol en Espanol

Tiratricol en Francais


Tiratricol in the Marketplace

Patents on Tiratricol

Experimental / Informatics

List of terms related to Tiratricol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue.


It is indicated in the management of thyroid hormone resistance syndrome[1] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

It has been investigated for use in reducing goiter.[2]

It has also shown some effectiveness in reducing the atrophy caused when using corticosteroids.[3]

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol.[4][5]

Legal status

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale.[6] Tiratricol is still available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer.[7] It is available as an orphan drug to be prescribed by registered specialists in Europe.


  1. Carvalho GA, Ramos HE (2004). "[Thyroid hormone resistance syndrome]". Arq Bras Endocrinol Metabol (in Portuguese). 48 (1): 83–92. PMID 15611821. doi:10.1590/S0004-27302004000100010.  Free full textPDF (95.3 KiB)
  2. Brenta G, Schnitman M, Fretes O; et al. (November 2003). "Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid". J. Clin. Endocrinol. Metab. 88 (11): 5287–92. PMID 14602763. doi:10.1210/jc.2003-030095. 
  3. Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J (November 2006). "Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans". Thyroid. 16 (11): 1157–62. PMID 17123343. doi:10.1089/thy.2006.16.1157. 
  4. "FDA Warns Against Consuming Dietary Supplements Containing Tiratricol" (Press release). U.S. Food and Drug Administration. November 21, 2000. Retrieved 2007-08-08. 
  5. "Health Canada issues warning on products containing Tiratricol (TRIAC)" (Press release). Health Canada. December 2, 1999. Retrieved 2007-08-08. 
  6. "Anvisa suspende Tiratricol" (in Portuguese). Brazilian Society of Endocrinology and Metabolism. Archived from the original on 2007-10-09. Retrieved 2007-08-08. 
  7. Laboratoires DB PHARMA: Teatrois information